Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO1108 Herpes Zoster Vaccine in Adults ≥ 40 Years
NCT07285278Phase 2Active, not recruiting
- Sponsor
- Abogen Bioscience
- Start
- Nov 2025
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ABO1108 in herpes zoster (HZ), sponsored by Abogen Bioscience. Started Nov 2025; status: active, not recruiting.
02
Drugs
ABO1108
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07285278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285278.